Clinical Significance of Bronchodilator Reversibility Testing: Standardizing Pre- and Post-Response Criteria Across Multi-Site Respiratory Labs
Bronchodilator reversibility testing is a core component of respiratory function testing, used to determine whether airflow obstruction is fixed or reversible after administering a short-acting bronchodilator. The clinical value of this test depends almost entirely on consistent application of bronchodilator response criteria across sites. Yet in practice, multi-site respiratory labs frequently apply different thresholds, reference equations, and interpretation frameworks, making cross-site comparison unreliable and patient management inconsistent.
TL;DR
Bronchodilator reversibility testing measures post-bronchodilator changes in lung function, most commonly FEV1, to classify obstruction as fixed or reversible.
Standardization of spirometry reversibility criteria across multi-site labs is a persistent clinical challenge with real patient safety implications.
Updated ERS/ATS guidelines have shifted the field toward using absolute values rather than percentage-based thresholds, but adoption remains uneven.
Inconsistent criteria application creates diagnostic variability that can affect treatment decisions, particularly for asthma and COPD.
Cloud-based respiratory reporting platforms with built-in, updatable normal values libraries can help labs stay aligned with evolving standards.
What Is Bronchodilator Reversibility Testing and Why Does It Matter?
Bronchodilator reversibility testing is the process of measuring lung function before and after administering a bronchodilator (typically salbutamol 400 mcg via spacer) to quantify how much airflow obstruction can be reversed pharmacologically. It is a standard step in respiratory function testing for conditions including asthma, COPD, and mixed obstructive-restrictive patterns.
The result is expressed as a bronchodilator response (BDR), most commonly measured as the change in FEV1 (forced expiratory volume in one second). According to a 2019 study published in the journal COPD by Barjaktarevic et al., the clinical significance of BDR varies depending on whether it is defined by post-bronchodilator change in FEV1 as a measure of flow, or by change in FVC as a measure of volume. The study found that these two measures reflect meaningfully different physiological phenomena and carry distinct clinical implications.
This distinction matters. A lab that only tracks FEV1 change may miss clinically significant volume responses, particularly in patients with air trapping or hyperinflation.
What Do the Current ERS/ATS Guidelines Say About Bronchodilator Response Criteria?
The interpretation of bronchodilator response criteria has evolved significantly. According to MDedge reporting on the updated ERS/ATS lung function interpretation guidelines, the traditional threshold of a 12% and 200 mL increase in FEV1 or FVC has been critically re-examined. The updated guidance noted that this threshold was based on limited evidence and that the biological variability in healthy individuals means a "positive" response using the old criteria does not always indicate true reversibility.
Key shifts in the updated ERS/ATS framework include:
Moving away from percentage-based thresholds toward z-score-based interpretation, which accounts for age, sex, height, and ethnicity.
Recognizing that a "significant" bronchodilator response should be interpreted in clinical context, not as a binary positive/negative result.
Acknowledging that bronchodilator testing results are inherently variable and should not be used as standalone diagnostic criteria.
As the MDedge summary noted, "administering a bronchodilator and measuring changes in lung function seems simple and intuitive," but the interpretation is far more nuanced than the test itself suggests.
Why Is Standardization Across Multi-Site Labs So Difficult?
Standardization of spirometry reversibility criteria across multiple sites is harder than it looks. The barriers are both technical and organizational:
Challenge | Root Cause |
|---|---|
Different spirometry equipment | Manufacturer-specific software applies different reference equations |
Inconsistent normal value libraries | Sites may use outdated or locally customized reference ranges |
Variable staff training | Interpretation practices differ between individual scientists |
Guideline lag | Labs may not update criteria when ERS/ATS releases new standards |
No centralized audit mechanism | Multi-site networks lack tools to compare interpretation consistency |
The result is that the same patient, tested at two different sites within the same health network, may receive different classifications of their bronchodilator response. This is not a hypothetical risk; it is a known limitation acknowledged in the clinical literature.
How Should Labs Define a "Significant" Bronchodilator Response in 2026?
There is no single universally agreed threshold, but current best practice guidance points toward the following framework:
Primary metric: Change in FEV1 and FVC, assessed using z-score-based reference equations rather than fixed percentage thresholds.
Contextual interpretation: A response should be interpreted alongside symptoms, baseline severity, and clinical history.
Volume vs. flow: As highlighted by Barjaktarevic et al., tracking both FEV1 (flow) and FVC (volume) responses captures a more complete physiological picture.
Reproducibility check: Variability between pre- and post-bronchodilator efforts should be assessed to ensure the response is real, not a technique artefact.
Avoid binary labelling: Classifying patients as simply "reversible" or "irreversible" oversimplifies a continuous physiological spectrum.
Labs that apply these principles consistently are better positioned to support accurate diagnosis and appropriate treatment escalation.
How Can Respiratory Labs Practically Improve Consistency in BDR Reporting?
Improving consistency in bronchodilator response criteria across sites requires both clinical governance and technical infrastructure. Practically, this means:
Adopt a shared normal values library that is centrally maintained and updated when guidelines change.
Standardize report templates so that pre- and post-bronchodilator values are always presented in the same format.
Configure software to flag when a response meets or exceeds defined thresholds, reducing reliance on individual scientist memory.
Conduct regular inter-site audits to compare how BDR is being interpreted across locations.
Invest in training that reflects current ERS/ATS guidance, not legacy practices.
This is where platforms like Rezibase provide practical value. Rezibase includes a pre-configured and regularly updated Normal Values Library, and its reporting module is structured around ATS guidelines. For multi-site networks, having all sites on the same cloud-based platform means everyone is working from the same reference framework, reducing the interpretive drift that accumulates when sites manage their own local configurations.
Frequently Asked Questions
What is bronchodilator reversibility testing used for?
It is used to determine whether airflow obstruction in a patient is partially or fully reversible after bronchodilator administration, supporting diagnosis and management of conditions like asthma and COPD.
What is the standard bronchodilator response threshold?
The traditional threshold has been a 12% and 200 mL increase in FEV1 or FVC. Updated ERS/ATS guidelines recommend moving toward z-score-based interpretation for greater accuracy.
Can bronchodilator response criteria differ between labs?
Yes. Differences in equipment, reference equations, and local protocols mean the same patient can receive different BDR classifications at different sites.
Should labs track FEV1 change only?
No. Tracking both FEV1 (flow) and FVC (volume) responses provides a more complete clinical picture, as noted in the Barjaktarevic et al. research.
How often should labs update their spirometry reversibility criteria?
Labs should review their criteria whenever major guideline updates are released by ERS or ATS, and at minimum every two to three years.
What role does software play in BDR standardization?
Respiratory reporting software that embeds current normal values and structured reporting templates significantly reduces inter-site variability in BDR interpretation.
Is a positive bronchodilator response diagnostic of asthma?
No. A positive response supports the diagnosis but should not be used as a standalone criterion. Clinical context is essential.
About Rezibase
Rezibase is Australia's most advanced cloud-based respiratory and sleep reporting platform, built by respiratory scientists for respiratory scientists. Trusted by over 35 sites including NHS in the UK and NSW Health in Australia, Rezibase helps labs stay aligned with evolving clinical standards through its regularly updated Normal Values Library, ATS-aligned reporting tools, and vendor-neutral data import capabilities. Learn more at rezibase.com.
Interested in how Rezibase supports standardized bronchodilator reporting across multi-site labs? Visit rezibase.com to explore the platform or book a demo.
References
Barjaktarevic IZ et al. Clinical Significance of Bronchodilator Responsiveness Evaluated by FO. Dove Press / COPD Journal. https://www.dovepress.com/clinical-significance-of-bronchodilator-responsiveness-evaluated-by-fo-peer-reviewed-fulltext-article-COPD
MDedge / The Hospitalist. The latest on ERS/ATS lung function interpretation guidelines and bronchodilator testing. https://blogs.the-hospitalist.org/content/latest-ers/ats-lung-function-interpretation-guidelines-and-bronchodilator-testing